Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.

doi:10.3390/curroncol31070299

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.

Current oncology (Toronto, Ont.) - 16 Jul 2024

Erker Craig, Vanan Magimairajan Issai, Larouche Valérie, Nobre Liana, Cacciotti Chantel, Vairy Stéphanie, Zelcer Shayna, Fleming Adam, Bouffet Eric, Jabado Nada, Legault Geneviève, Renzi Samuele, McKeown Tara, Crooks Bruce, Thacker Nirav, Ramaswamy Vijay, Coltin Hallie, Lafay-Cousin Lucie, Cheng Sylvia, Hukin Juliette, Climans Seth Andrew, Lim-Fat Mary Jane, McKillop Sarah, Lapointe Sarah, Alves Mélanie, Bennett Julie, Tabori Uri, Perreault Sébastien

Abstract excerpt

Background: The treatment of BRAF V600E gliomas with BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been increasingly integrated into clinical practice for pediatric low-grade gliomas (PLGGs) and pediatric high-grade gliomas (HGGs). However, some questions remain unanswered, such as the best time to start targeted therapy, duration of treatment, and discontinuation of therapy. Given that no clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 39057171
DOI: 10.3390/curroncol31070299
PMCID: PMC11276207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.PMID 39057171Read ↗

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read ↗

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System TumorsSemantic proximity Read ↗

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutationSemantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

[Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].Semantic proximity Read ↗

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read ↗

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.Semantic proximity Read ↗

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.Semantic proximity Read ↗

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.Semantic proximity Read ↗

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.Semantic proximity Read ↗

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.Semantic proximity Read ↗

Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.